308 related articles for article (PubMed ID: 29399721)
21. Role of Major Endocannabinoid-Binding Receptors during Mouse Oocyte Maturation.
Cecconi S; Rossi G; Oddi S; Di Nisio V; Maccarrone M
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212770
[TBL] [Abstract][Full Text] [Related]
22. [The endocannabinoid system and its role in regulation of metabolism in peripheral tissues].
Rumińska A; Dobrzyń A
Postepy Biochem; 2012; 58(2):127-34. PubMed ID: 23214136
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids and Pain: Sites and Mechanisms of Action.
Starowicz K; Finn DP
Adv Pharmacol; 2017; 80():437-475. PubMed ID: 28826543
[TBL] [Abstract][Full Text] [Related]
24. Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?
Hinden L; Tam J
Nephron; 2019; 143(1):24-27. PubMed ID: 30636250
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
Tam J
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
[TBL] [Abstract][Full Text] [Related]
26. Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray.
Almeida-Santos AF; Gobira PH; Rosa LC; Guimaraes FS; Moreira FA; Aguiar DC
Behav Brain Res; 2013 Sep; 252():10-7. PubMed ID: 23714073
[TBL] [Abstract][Full Text] [Related]
27. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
Jourdan T; Park JK; Varga ZV; Pálóczi J; Coffey NJ; Rosenberg AZ; Godlewski G; Cinar R; Mackie K; Pacher P; Kunos G
Diabetes Obes Metab; 2018 Mar; 20(3):698-708. PubMed ID: 29106063
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoid system in neurodegenerative disorders.
Basavarajappa BS; Shivakumar M; Joshi V; Subbanna S
J Neurochem; 2017 Sep; 142(5):624-648. PubMed ID: 28608560
[TBL] [Abstract][Full Text] [Related]
30. Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function.
Vilches-Flores A; Hauge-Evans AC; Jones PM; Persaud SJ
Clin Sci (Lond); 2013 Apr; 124(7):467-78. PubMed ID: 23078523
[TBL] [Abstract][Full Text] [Related]
31. A Guide to Targeting the Endocannabinoid System in Drug Design.
Stasiulewicz A; Znajdek K; Grudzień M; Pawiński T; Sulkowska AJI
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316328
[TBL] [Abstract][Full Text] [Related]
32. Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice.
Troy-Fioramonti S; Demizieux L; Gresti J; Muller T; Vergès B; Degrace P
Diabetes; 2015 Mar; 64(3):808-18. PubMed ID: 25281429
[TBL] [Abstract][Full Text] [Related]
33. [The endocannabinoid system and bone].
Pura M; Vaňuga P
Vnitr Lek; 2016; 62(9 Suppl 3):99-102. PubMed ID: 27734700
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects.
Braunscheidel KM; Okas MP; Floresco SB; Woodward JJ
Psychopharmacology (Berl); 2022 May; 239(5):1337-1347. PubMed ID: 34291308
[TBL] [Abstract][Full Text] [Related]
35. Role of Cannabinoid Signaling in Cardiovascular Function and Ischemic Injury.
Rorabaugh BR; Guindon J; Morgan DJ
J Pharmacol Exp Ther; 2023 Dec; 387(3):265-276. PubMed ID: 37739804
[TBL] [Abstract][Full Text] [Related]
36. The endocannabinoid system in neuropathological states.
Orgado JM; Fernández-Ruiz J; Romero J
Int Rev Psychiatry; 2009 Apr; 21(2):172-80. PubMed ID: 19367511
[TBL] [Abstract][Full Text] [Related]
37. Interaction between Cannabinoid Type 1 and Type 2 Receptors in the Modulation of Subventricular Zone and Dentate Gyrus Neurogenesis.
Rodrigues RS; Ribeiro FF; Ferreira F; Vaz SH; Sebastião AM; Xapelli S
Front Pharmacol; 2017; 8():516. PubMed ID: 28848435
[TBL] [Abstract][Full Text] [Related]
38. Modification on the 1,2-dihydro-2-oxo-pyridine-3-carboxamide core to obtain multi-target modulators of endocannabinoid system.
Gado F; Arena C; Fauci C; Reynoso-Moreno I; Bertini S; Digiacomo M; Meini S; Poli G; Macchia M; Tuccinardi T; Gertsch J; Chicca A; Manera C
Bioorg Chem; 2020 Jan; 94():103353. PubMed ID: 31668465
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.
Brennecke B; Gazzi T; Atz K; Fingerle J; Kuner P; Schindler T; Weck G; Nazaré M; Grether U
Pharm Pat Anal; 2021 May; 10(3):111-163. PubMed ID: 34111979
[TBL] [Abstract][Full Text] [Related]
40. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor.
Chiurchiù V; Lanuti M; Catanzaro G; Fezza F; Rapino C; Maccarrone M
Atherosclerosis; 2014 Mar; 233(1):55-63. PubMed ID: 24529123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
